Designing MSC Programs for Scale: Avoiding Early Decisions That Derail Commercialization

Mesenchymal stromal cell (MSC) therapies continue to show promise across a wide range of indications, but translating early scientific success into scalable, reproducible, and commercially viable products remains a persistent challenge.

Many of the obstacles that emerge late in development, during scale-up, tech transfer, or regulatory review, can be traced back to decisions made far earlier in discovery and process development.

Dr. John “Yoshi” Shyu, chief scientific officer and director of commercial technology at Corning Life Sciences, has spent more than a decade working alongside pharmaceutical and biotechnology teams to help bridge this gap.

In this article, Shyu shares insights into where programs most often go off track, what inflection points are consistently underestimated, and how sponsors can design MSC development strategies that support both regulatory success and long-term commercialization. 

Culture system decisions shape downstream manufacturability

What early decisions in MSC discovery and process development most often create downstream barriers?

One of the most common sources of downstream friction, Shyu explained, stems from early culture system selection. In discovery, platforms are often chosen for convenience, familiarity, or short-term biological performance, rather than their ability to translate into commercial manufacturing.

“Culture platforms, media formulations, and vessel formats that perform well at bench scale are often selected based on convenience or historical use rather than scalability or commercial intent,” Shyu said.

“As development progresses, these systems frequently fail to translate to large-scale manufacturing that aligns with the intended batch size, dosing strategy, or therapeutic indication,” he added.

Processes can become labor-intensive, difficult to automate, and vulnerable to contamination. Limited control over critical process parameters undermines batch-to-batch reproducibility and makes validation more complex.

The result is often a forced process redesign late in development, which can delay timelines, inflate costs, and introduce additional regulatory risk. Shyu emphasized that the goal should be to select culture platforms that can bridge discovery, development, and commercial manufacturing without requiring fundamental changes.

What this means in practice:

• Early culture system choices must account for scalability, automation readiness, and GMP compatibility.
• Research platforms that rely on open, manual operations create cost, contamination, and reproducibility risks.
• Selecting systems designed to scale reduces the likelihood of late-stage process overhauls.

Overlooked scalability inflection points in early development

What are the most underestimated scalability inflection points that sponsors tend to miss until it’s too late?

While scale-up challenges are well known, certain inflection points consistently catch sponsors off guard. One of the most underestimated, according to Shyu, is media.

“Sponsors often realize too late that media selected during early development cannot be economically sourced, prepared, or managed at commercial scale,” he noted.

Media costs and volumes tend to increase faster than anticipated, quickly dominating cost of goods sold (COGS). A formulation that performs well biologically in small volumes may be prohibitively expensive or operationally complex when multiplied across commercial batches.

 

“This highlights why media selection must be considered not only from a biological performance standpoint, but as part of an integrated process design that supports scalability, supply reliability, and long-term cost control,” Shyu added.

Another overlooked inflection point is closed-system integration. Processes optimized in open or semi-open formats during early development can be difficult to retrofit into the closed, automated environments expected for commercial manufacturing.

“Retrofitting these processes later can introduce significant technical risk, delays, and capital expense; issues that are far easier to mitigate if addressed early in process design,” Shyu explained.

 

Key inflection points to plan for early:

• Media sourcing, scalability, preparation, and long-term cost implications.
• The transition from open development workflows to closed, automated manufacturing systems.
• The cumulative impact of late retrofits on timelines, risk, and capital requirements. 

Embedding regulatory and commercial requirements from the outset

What advice would you give to sponsors on how to design programs that are built for regulatory and commercial success from day one?

For Shyu, the common thread behind successful MSC programs is a lifecycle-driven mindset that integrates development, manufacturing, and regulatory strategy from the outset.

“First, start with the end in mind,” he advised. “This means defining the intended commercial state upfront and selecting GMP-compliant, scalable materials and technologies as early as possible.”

Shyu also cautioned against prioritizing peak performance at the expense of robustness.

“Regulatory agencies prioritize reproducibility, process understanding, and control strategies over maximum throughput or growth rates,” he said.

Finally, flexibility should be engineered into the process. “Incorporating platforms or technologies that support both scale-up and scale-out can help sponsors respond more easily to changes in demand, facility constraints, or regulatory requirements,” Shyu explained.

Designing with future automation in mind further improves consistency and reduces operator-driven variability.

Design principles that support long-term success:

• Align early on the intended commercial state, not just the next development milestone.
• Prioritize process robustness and reproducibility over maximum short-term performance.
• Build flexibility and automation readiness into manufacturing strategies from the start. 

How early collaboration prevents late-stage redesigns

What kinds of collaboration are most effective in preventing costly process redesigns later in development?

Avoiding late-stage process changes requires more than good technological choices; it also depends on how teams collaborate. Shyu stressed the value of early, cross-functional, and data-driven partnerships that bring development, manufacturing, quality, and regulatory perspectives together.

In Corning’s customer engagements, the focus is on fit-for-purpose recommendations rather than short-term fixes. This integrated approach helps identify risks early and align requirements across functions before decisions become difficult to reverse.

“Engaging stakeholders upfront allows design decisions to be evaluated not only for performance, but also for manufacturability, quality, scalability, and regulatory compliance,” Shyu explained.

By treating collaboration as a continuous process rather than a handoff between stages, teams can reduce rework, minimize delays, and maintain momentum as programs advance.

Effective collaboration strategies include:

• Early involvement of manufacturing, quality, and regulatory stakeholders.
• Data-driven decision-making that considers downstream implications.
• Partnering for integrated, end-to-end perspectives rather than isolated optimizations. 

Regional variation and the push toward harmonized MSC platforms

Do you see differences in how teams in different regions approach MSC development and manufacturing planning? What best practices would you like to see adopted more widely across the industry?

MSC development strategies vary by geography. “Each geographic region operates under distinct regulatory frameworks, with agencies that emphasize different values and approval requirements,” Shyu said. “These regulatory expectations strongly influence sponsor and developer behavior and, in turn, shape MSC therapeutic strategies.”

Shyu also noted variability in expectations around biological data, process control, comparability strategies, material traceability, and preferred manufacturing models, such as centralized vs decentralized production. Access to patient populations and regional supply chain considerations further shape development pathways.

 

“Together, these factors make each region relatively unique in how MSC therapies are developed, manufactured, and ultimately delivered to patients,” he stated.

As regulatory agencies move toward greater harmonization, platforms capable of standardization, while accommodating regional differences, will become increasingly important for global commercialization.

 

Regional realities sponsors must navigate:

• Divergent regulatory expectations across regions.
• Differences in supply chain design, material origin, and traceability requirements.
• The growing need for standardized platforms adaptable to local constraints. 

Emerging technologies reshaping MSC scalability and cost dynamics

Which emerging technologies or process innovations do you believe will have the greatest impact on making MSC therapies scalable, cost-effective, and commercially achievable?

Looking ahead, Shyu believes that no single breakthrough will solve MSC scalability. Instead, progress will come from coordinated advances across biology, manufacturing, and analytics.

“From a biological standpoint, emerging technologies that improve MSC attachment, expansion efficiency, and phenotypic stability will have a major impact,” Shyu stated. Advances in surface chemistries, microcarriers, and culture media that reduce donor-to-donor variability can significantly improve product consistency and quality, while minimizing phenotypic drift will be important for late-stage commercialization.

From a manufacturing perspective, closed, automated, and single-use bioreactor systems offer clear advantages. These approaches improve reproducibility, reduce contamination risk, and lower labor intensity, directly addressing one of the core barriers to MSC commercialization: high COGS.

Finally, Shyu highlighted the transformative potential of advanced process analytical technologies (PAT).

“Real-time or near-real-time tools that monitor cell mass, culture conditions, and metabolic states would enable tighter process control, early detection of deviations, and more robust scale-up,” he said.

When combined with data analytics and AI-driven optimization, PAT can accelerate development while increasing regulatory confidence in process understanding and control.

 

High-impact innovation areas to watch:

• Technologies that stabilize MSC phenotype while increasing yield.
• Closed, automated, and single-use manufacturing systems.
• Real-time analytics and data-driven process optimization.

 

 

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.